학술논문
Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience
Document Type
Article
Author
Source
In Leukemia Research May 2024 140
Subject
Language
ISSN
0145-2126